Neurometrix (NASDAQ:NURO) Trading Up 8.7%

Neurometrix Inc (NASDAQ:NURO) was up 8.7% during mid-day trading on Wednesday . The stock traded as high as $5.42 and last traded at $4.99, approximately 209,700 shares were traded during trading. An increase of 889% from the average daily volume of 21,195 shares. The stock had previously closed at $4.59.

NURO has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Neurometrix in a report on Friday, October 18th. Zacks Investment Research raised shares of Neurometrix from a “hold” rating to a “buy” rating and set a $0.25 price target for the company in a report on Wednesday, October 23rd. Finally, ValuEngine downgraded shares of Neurometrix from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th.

The business’s fifty day simple moving average is $1.53 and its two-hundred day simple moving average is $0.71.

Neurometrix (NASDAQ:NURO) last issued its quarterly earnings results on Thursday, October 17th. The medical device company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. Neurometrix had a negative net margin of 48.86% and a negative return on equity of 65.19%. The firm had revenue of $2.09 million during the quarter, compared to the consensus estimate of $3.94 million. As a group, equities analysts anticipate that Neurometrix Inc will post -3 EPS for the current year.

A hedge fund recently raised its stake in Neurometrix stock. Sabby Management LLC raised its stake in Neurometrix Inc (NASDAQ:NURO) by 15.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 934,212 shares of the medical device company’s stock after purchasing an additional 124,730 shares during the period. Sabby Management LLC owned approximately 95.33% of Neurometrix worth $299,000 as of its most recent SEC filing.

Neurometrix Company Profile (NASDAQ:NURO)

NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.

Featured Article: How can you know how many shares are floating?

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.